BBB National Programs Decision Summaries
BBB National Programs provides summaries of all case decisions from the National Advertising Division (NAD), National Advertising Review Board (NARB), Children’s Advertising Review Unit (CARU), Direct Selling Self-Regulatory Council (DSSRC), and Digital Advertising Accountability Program (DAAP). Subscribe to receive a weekly wrap-up of published case decisions in your inbox.
- All
-
1/13/2015 - NAD Recommends P&G Discontinue Claims Made for Swiffer Sweeper Following Challenge by Libman Broom Maker
The National Advertising Division has recommended that The Procter & Gamble Company, maker of Swiffer Sweeper products, discontinue superior performance claims challenged by The Libman Company, maker of Libman brooms. -
1/13/2015 - NAD Examines Implied Claims for FIOS Quantum Following Cablevision Challenge
The National Advertising Division has determined that Verizon Communications, Inc., has provided a reasonable basis for advertising claims that FiOS Quantum TV subscribers can record up to 12 shows at once, watch TV “on the go,” store up to 200 hours of HD programming, and watch recorded programming in other rooms. -
1/08/2015 - NAD Finds Lifes2Good Can Support Certain Claims for the Company’s Viviscal Supplement; Recommends Advertiser Discontinue One Claim
The National Advertising Division has determined that Lifes2Good, Inc., can support certain claims for the company’s Viviscal dietary supplement, a product promoted to women with thinning hair. -
1/07/2015 - NAD Recommends Terra Novo Modify, Discontinue Certain Claims for Erosion Product; Finds Advertiser Can Support Certain Claims
The National Advertising Division has recommended that Terra Novo, Inc., modify or discontinue certain advertising claims for the company’s erosion control products. NAD determined, however, that the advertiser’s evidence served to support certain advertising claims. -
1/06/2015 - NAD Recommends Novartis Discontinue Onset-of-Action Claim for Theraflu, following Pfizer Challenge
The National Advertising Division has recommended that Novartis Consumer Health Inc., discontinue the advertising claim that “Theraflu Multi-Symptom Severe Cold” “starts to get to work in your body in 5 minutes.” The claim was challenged by Pfizer Consumer Healthcare, a competing manufacturer of cold and cough relief products. -
1/05/2015 - NAD Refers Advertising Claims from Cortec Corp. to FTC for Further Review
The National Advertising Division has referred to the Federal Trade Commission (FTC) advertising claims made by Cortec Corporation, the maker of vapor corrosion inhibiting (VCI) products, after the advertiser declined to participate in a self-regulatory review of its advertising claims. -
12/23/2014 - NAD Refers Advertising for Obesity Research Council’s ‘Lipozene’ to FTC for Review after Advertiser Declines to Participate in NAD Proceeding
The National Advertising Division has referred advertising for Lipozene, a product marketed by the Obesity Research Council, to the Federal Trade Commission (FTC) after the company declined to participate in NAD’s review of its advertising claims. -
12/17/2014 - NAD Examines Fareportal’s Search Engine Marketing in Challenge Brought by Expedia
The National Advertising Division has recommended that online travel agent Fareportal Inc. – operator of the CheapOair.com and OneTravel.com sites –discontinue certain claims in its search engine marketing as the claims could potentially mislead consumers when they appear in response to consumer searches. -
12/04/2014 - Sumo Logic Discontinues Express, Implied Claims Challenged by Splunk
Sumo Logic, Inc., the maker of software for log management and analytic systems, has said it will discontinue all advertising claims challenged before the National Advertising Division (NAD) by competitor Splunk, Inc. -
12/03/2014 - NAD Recommends ADD-Care Discontinue Claims for Supplement Promoted for ‘Help’ with ADD, ADHD Symptoms
The National Advertising Division has recommended that ADD-care, the maker of the dietary supplement ADD-care, discontinue all claims for the product reviewed by NAD in a recent proceeding.